Nektar Therapeutics
NKTRFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Nektar Therapeutics Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 17 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 18, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Nektar Therapeutics's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-05-19 · ROBIN HOWARD W: Larger than 115 of the 127 other insider sales of Common Stock on file. SEC filing
- 2025-02-19 · ROBIN HOWARD W: Larger than 116 of the 127 other insider sales of Common Stock on file. SEC filing
- 2024-12-23 · Wilson Mark Andrew: Larger than 119 of the 127 other insider sales of Common Stock on file. SEC filing
- 2024-12-19 · Zalevsky Jonathan: Larger than 124 of the 127 other insider sales of Common Stock on file. SEC filing
- 2024-12-18 · ROBIN HOWARD W: Larger than all 127 other insider sales of Common Stock on file. SEC filing
- 2024-12-17 · ROBIN HOWARD W: Larger than 123 of the 127 other insider sales of Common Stock on file. SEC filing
- 2024-05-10 · KROIN DAVID: Larger than 125 of the 127 other insider sales of Common Stock on file. SEC filing
- 2023-06-14 · WHITFIELD ROY A: Larger than 117 of the 127 other insider sales of Common Stock on file. SEC filing
- 2022-11-16 · ROBIN HOWARD W: Larger than 121 of the 127 other insider sales of Common Stock on file. SEC filing
- 2022-08-18 · Zalevsky Jonathan: Larger than 126 of the 127 other insider sales of Common Stock on file. SEC filing
- 2022-05-16 · ROBIN HOWARD W: Larger than 120 of the 127 other insider sales of Common Stock on file. SEC filing
- 2021-11-16 · ROBIN HOWARD W: Larger than 122 of the 127 other insider sales of Common Stock on file. SEC filing
- 2021-05-17 · Zalevsky Jonathan: Larger than 118 of the 127 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-17 | ROBIN HOWARD W · President & CEO | Common Stock | S — Open market or private sale | −5,500 | 60.81 | SEC filing |
| 2026-06-17 | ROBIN HOWARD W · President & CEO | Common Stock | S — Open market or private sale | −4,500 | 61.65 | SEC filing |
| 2026-06-16 | ROBIN HOWARD W · President & CEO | Common Stock | S — Open market or private sale | −5,303 | 59.97 | SEC filing |
| 2026-06-16 | ROBIN HOWARD W · President & CEO | Common Stock | S — Open market or private sale | −4,697 | 60.71 | SEC filing |
| 2026-06-15 | Zalevsky Jonathan · Chief R&D Officer | Common Stock | S — Open market or private sale | −5,538 | 60.71 | SEC filing |
| 2026-05-19 | ROBIN HOWARD W · President & CEO | Common Stock | S — Open market or private sale | −444 | 65.51 | SEC filing |
| 2026-05-19 | Zalevsky Jonathan · Chief R&D Officer | Common Stock | S — Open market or private sale | −199 | 65.51 | SEC filing |
| 2026-02-18 | ROBIN HOWARD W · President & CEO | Common Stock | S — Open market or private sale | −423 | 73.00 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-12-22 | ROBIN HOWARD W · President & CEO | Common Stock | A — Grant, award, or other acquisition | +21,667 | SEC filing |
| 2025-12-22 | Zalevsky Jonathan · Chief R&D Officer | Stock Option | A — Grant, award, or other acquisition | +25,000 | SEC filing |
| 2025-12-22 | ROBIN HOWARD W · President & CEO | Stock Option | A — Grant, award, or other acquisition | +86,667 | SEC filing |
| 2025-12-22 | Zalevsky Jonathan · Chief R&D Officer | Common Stock | A — Grant, award, or other acquisition | +6,250 | SEC filing |
| 2025-11-21 | Zalevsky Jonathan · Chief R&D Officer | Stock Option | A — Grant, award, or other acquisition | +4,766 | SEC filing |
| 2025-11-21 | ROBIN HOWARD W · President & CEO | Stock Option | A — Grant, award, or other acquisition | +12,170 | SEC filing |
| 2025-11-21 | Wilson Mark Andrew · Chief Legal Officer | Stock Option | A — Grant, award, or other acquisition | +3,400 | SEC filing |
| 2025-11-21 | Wilson Mark Andrew · Chief Legal Officer | Common Stock | A — Grant, award, or other acquisition | +1,903 | SEC filing |
Showing 8 of 22 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.